Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma

April 25th 2024

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma

April 23rd 2024

Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

FDA Grants Accelerated Approval to Tovorafenib for Pediatric Relapsed/Refractory BRAF+ Low-Grade Glioma

April 23rd 2024

The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes

April 17th 2024

The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.

FDA Grants Fast Track Designation to TLX101-CDx for Imaging Progressive/Recurrent Glioma

April 16th 2024

The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

April 9th 2024

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

VBI-1901 Elicits Disease Control in Recurrent Glioblastoma

April 3rd 2024

The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.

Raising Hope

March 18th 2024

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

Novel CAR T-Cell Therapy Displays Activity in Glioblastoma

March 18th 2024

Treatment with a next-generation CAR T-cell agent displayed early efficacy in a small group of patients with glioblastoma.

Dual-Targeted CAR T-Cell Therapy Displays Early Efficacy in Recurrent Glioblastoma

March 13th 2024

A CAR T-cell therapy directed toward 2 brain tumor–associated proteins displayed preliminary activity in recurrent glioblastoma.

FDA and EMA Accept Regulatory Submissions for Vorasidenib for IDH-Mutant Diffuse Glioma

February 20th 2024

Vorasidenib has been granted regulatory submission acceptance by the FDA and EMA for IDH-mutant diffuse glioma.

FDA Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma

February 13th 2024

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

NCCN Releases First Neuroblastoma Treatment Recommendations

February 12th 2024

The NCCN has published the first set of treatment recommendations for neuroblastoma.

Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

January 24th 2024

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

January 8th 2024

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

EO2401 Plus Nivolumab and Bevacizumab Shows Activity in Progressive/Recurrent Glioblastoma

November 20th 2023

The use of the first-in-class, microbiome-derived therapeutic vaccine EO2401 in combination with nivolumab with or without bevacizumab produced clinical activity and was well tolerated in patients with progressive/recurrent glioblastoma.

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15th 2023

The FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an announcement from Rznomics Inc.

FG001 Meets Detection End Point in High-Grade Glioma

November 14th 2023

The use of the optical imaging agent FG001 led to the detection of additional cancer by optical guidance in patients with high-grade glioma, meeting the primary end point of the phase 2b FG001-CT-001 trial.

VAL-083 Fails to Outperform SOC in Glioblastoma

October 31st 2023

VAL-083 did not improve efficacy compared with standard-of-care approaches in patients with glioblastoma.